治疗前MRI参数预测子宫腺肌症地诺孕素短期疗效
回顾性队列纳入78例MRI诊断的子宫腺肌症患者,其中46例接受地诺孕素治疗,30例应答、16例无应答。分析治疗前T2信号比、DWI信号比、ADC值及子宫形态参数。结果显示ADC绝对值及相对子宫内膜的ADC信号比与短期应答相关,AUC均为0.70,而腺肌症亚型及形态参数无显著关联。
要点
- ADC较高的地诺孕素治疗患者短期临床应答更好,阅片时可关注ADC绝对值。
- MRI腺肌症亚型及病灶分布不能预测地诺孕素短期应答,报告不必据此分层。
- ADC相对子宫内膜信号比可作为辅助分层指标,但AUC中等,需谨慎解读。
核心结论
- 治疗前定量扩散MRI参数与地诺孕素短期临床应答相关,常规形态学特征无显著相关。
- DWI可能为地诺孕素治疗的子宫腺肌症分层提供补充影像生物标志物。
研究设计与样本
- 回顾性队列研究,纳入2018年10月至2025年7月78例MRI诊断的子宫腺肌症患者。
- 所有患者在激素治疗前接受盆腔MRI检查,46例接受地诺孕素治疗。
- 定量MRI参数包括T2信号强度比、DWI信号强度比、标准化ADC及子宫形态参数。
- 腺肌症亚型依据改良Kishi标准分类,短期应答在治疗开始后3至6个月评估。
- 临床应答为复合结局,包括症状改善与治疗持续;预测分析仅限地诺孕素队列。
关键影像表现/征象
- MRI腺肌症亚型、病灶分布及子宫形态参数在应答组与非应答组间无显著差异。
- 应答组绝对ADC值显著高于非应答组,ADC相对子宫内膜信号比也显著更高。
- ADC与ADC相对子宫内膜信号比的最佳界值分别为0.951×10⁻³ mm²/s和0.952。
诊断标准与关键数值
- 绝对ADC值:应答组1.03×10⁻³ mm²/s,非应答组0.89×10⁻³ mm²/s,P=0.036。
- ADC相对子宫内膜信号比:应答组0.92,非应答组0.85,P=0.034。
- ADC与ADC相对子宫内膜信号比的ROC曲线下面积均为0.70。
- ADC最佳界值0.951×10⁻³ mm²/s,ADC相对子宫内膜信号比最佳界值0.952。
临床应用与阅片要点
- 阅片时可测量病灶ADC绝对值及相对子宫内膜的ADC信号比,辅助预判地诺孕素短期疗效。
- 腺肌症亚型及形态学表现在报告中不必作为地诺孕素疗效预测依据。
- 两个ADC相关参数AUC仅为0.70,不能单独用于决定治疗方案。
局限性
- 回顾性单中心研究设计,样本量较小。
- 随访时间短,缺乏前瞻性验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To evaluate whether pretreatment magnetic resonance imaging (MRI) parameters can predict short-term clinical response to dienogest (DNG) in patients with adenomyosis.
METHODS: This retrospective study included 78 patients with MRI-diagnosed adenomyosis who underwent pelvic MRI before hormonal therapy between October 2018 and July 2025. Quantitative MRI parameters included T2 signal intensity ratios, diffusion-weighted imaging (DWI) signal intensity ratios, normalized apparent diffusion coefficient (ADC), and uterine morphological parameters. Adenomyosis subtypes were classified according to the modified Kishi criteria. Short-term clinical response was assessed primarily 3-6 months after treatment initiation as a composite clinical outcome encompassing symptom improvement (dysmenorrhea, menstrual blood loss, and/or hemoglobin levels) and treatment continuation; patients were classified as responders or non-responders. Predictive analyses were restricted to the DNG cohort because only one patient in the GnRH cohort was a non-responder.
RESULTS: Of the 78 patients, 32 received gonadotropin-releasing hormone (GnRH) agonist or antagonist therapy and 46 received DNG. In the DNG cohort, 30 patients were responders and 16 were non-responders. MRI-based adenomyosis subtype, lesion distribution, and uterine morphological parameters were not significantly associated with response in DNG-treated patients. However, absolute ADC values were significantly higher in responders (1.03 vs. 0.89 × 10⁻3 mm2/s, P = 0.036), as was the ADC signal intensity ratio relative to the endometrium (ADC SIRendo: 0.92 vs. 0.85, P = 0.034). Receiver operating characteristic analysis demonstrated moderate discrimination for both parameters (area under the curve = 0.70). Optimal cut-off values were 0.951 × 10⁻3 mm2/s for ADC and 0.952 for ADC SIRendo.
CONCLUSION: Quantitative diffusion MRI parameters were associated with short-term clinical response to DNG, whereas conventional morphological features were not. Diffusion-weighted MRI may provide complementary imaging biomarkers for adenomyosis stratification in DNG-treated patients; prospective validation with longer follow-up is warranted.
引用
- Morikawa, Baba, Kusada, et al. Pretreatment MRI parameters as predictive biomarkers for short-term clinical response to dienogest in adenomyosis: a retrospective cohort study. Abdom Radiol (NY). 2026. PMID: 42313171. doi:10.1007/s00261-026-05592-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。